Investment Thesis
GT Biopharma is a pre-revenue pharmaceutical company experiencing severe financial distress with $12.9M annual cash burn against only $6.8M in cash reserves, creating a 6-month operational runway. Despite marginal improvement in losses year-over-year, zero revenue generation, total absence of capital investment, and negative ROE/ROA of -490%/-349.8% indicate fundamental business viability failure.
Strengths
- Strong liquidity position with 3.50x current ratio and $6.8M cash on hand
- Zero debt burden provides financial flexibility and avoids bankruptcy risk from leverage
- Improving net loss trend with 17.7% YoY improvement reducing operating burn
Risks
- Zero revenue generation indicating complete failure to commercialize products or execute business model
- Cash runway of only ~6 months at current burn rate of $12.9M annually
- Severely negative returns on equity (-490%) and assets (-349.8%) destroying shareholder value
- No capital expenditure or R&D investment visible suggesting stalled product development
- Deeply negative EPS of -$6.68 per share unsustainable long-term
- Zero insider buying activity in 90 days indicates no management confidence in recovery
Key Metrics to Watch
- Monthly cash burn rate and remaining liquidity runway
- Revenue initiation or clinical trial milestone announcements
- Operating cash flow stabilization or improvement
- Debt issuance or equity raise announcements indicating survival financing needs
Financial Metrics
Revenue
0.0
Net Income
-28.4M
EPS (Diluted)
$-6.68
Free Cash Flow
-12.9M
Total Assets
8.1M
Cash
6.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-490.0%
ROA
-349.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.50x
Quick Ratio
3.50x
Debt/Equity
0.00x
Debt/Assets
16.3%
Interest Coverage
-58.32x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T21:06:28.425403 |
Data as of: 2025-12-31 |
Powered by Claude AI